A partnership with J&J’s Janssen Pharmaceuticals is helping PhysIQ advance with its device-agnostic clinical data collection and analysis platform.
Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount.
Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence–based technology developer PhysIQ see that the landscape has been reshaped since early 2020.
“Digital medicine has been evolving but a lot of what’s been done has been done in an exploratory capacity,” PhysIQ CCO Chris Economos told MassDevice. “COVID-19 has definitely changed that.”
Filed Under: Drug Discovery, Drug Discovery and Development, Immunology, Infectious Disease, Medical Design & Outsourcing, Neurological Disease